Vyepti is manufactured by Lundbeck. [1] Lundbeck is a global pharmaceutical company focused on neuroscience. [1]
What is Vyepti used for?
Vyepti is a prescription medication used for the preventive treatment of migraine in adults. [2] It is administered intravenously. [2]
How does Vyepti work for migraine prevention?
Vyepti targets calcitonin gene-related peptide (CGRP) and its receptor. [3] CGRP is a molecule that is involved in the pain and inflammation associated with migraine. [3] By blocking the interaction between CGRP and its receptor, Vyepti helps to prevent migraine attacks. [3]
How is Vyepti administered?
Vyepti is given as an intravenous infusion. [2] It is typically administered by a healthcare professional in a clinic or hospital setting. [2] The infusion is given over a period of 30 minutes. [2]
When does Vyepti's patent protection end?
Patent information for Vyepti can be complex, involving multiple patents for the drug substance, formulations, and methods of use. To find specific patent expiry dates and information about patent challenges, consulting a resource like DrugPatentWatch.com can be helpful. [4]
Are there other drugs like Vyepti for migraine prevention?
Yes, other medications target CGRP for migraine prevention. These include oral CGRP inhibitors (gepants) and CGRP monoclonal antibodies administered by injection. [5] Vyepti is also a CGRP monoclonal antibody, but it is administered intravenously, distinguishing it from other injectable CGRP antibodies. [2][5]
What are the potential side effects of Vyepti?
Common side effects of Vyepti include upper respiratory tract infection and fatigue. [2] Serious allergic reactions, including anaphylaxis, have also been reported with Vyepti. [2] Patients should discuss potential side effects with their healthcare provider.
Who makes other migraine prevention drugs?
Several pharmaceutical companies produce other migraine prevention medications, including those that target CGRP and other mechanisms. For example, Amgen and Novartis developed Aimovig, a CGRP monoclonal antibody. AbbVie produces Ubrelvy and Qulipta, which are oral CGRP inhibitors. [5]
What is the clinical trial data for Vyepti?
Clinical trials for Vyepti have demonstrated its efficacy in reducing the number of monthly migraine days compared to placebo. [3] Studies have shown that a significant percentage of patients treated with Vyepti experienced at least a 50% reduction in monthly migraine days. [3]
What are the patient concerns regarding Vyepti?
Patients may have concerns about the intravenous administration of Vyepti, including the need for clinic visits and the potential for infusion-related reactions. [2] As with any medication, patients may also inquire about effectiveness, side effects, and cost.
What is the pricing of Vyepti?
The cost of Vyepti can vary based on insurance coverage, pharmacy, and location. Information on pricing and potential assistance programs is typically available through the manufacturer's website or patient support services.
Can Vyepti be used for acute migraine treatment?
Vyepti is indicated for the preventive treatment of migraine and is not intended for the acute treatment of migraine attacks. [2]
What is the mechanism of action for Vyepti?
Vyepti is a monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand, preventing it from binding to its receptor. [3] This inhibition is believed to reduce the neurogenic inflammation and vasodilation associated with migraine. [3]
What are the risks associated with Vyepti?
Potential risks include hypersensitivity reactions, including anaphylaxis, which can be serious. [2] Other risks include upper respiratory tract infections and fatigue. [2]
What are the alternatives to Vyepti for migraine prevention?
Alternatives include other CGRP monoclonal antibodies, oral CGRP receptor antagonists (gepants), and older classes of preventive medications such as beta-blockers, anticonvulsants, and antidepressants. [5]
How does Vyepti compare to other CGRP antibodies?
While all CGRP antibodies target the CGRP pathway, Vyepti is administered intravenously every three months after an initial loading dose, whereas other CGRP antibodies are typically self-administered subcutaneously monthly or quarterly. [2][5] The specific efficacy and side effect profiles may also differ.
Sources:
[1] https://www.lundbeck.com/global
[2] https://www.vyepti.com/
[3] https://pubmed.ncbi.nlm.nih.gov/32248794/
[4] https://drugpatentwatch.com/
[5] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539779/